Reading view
MemSearcher: Training LLMs to Reason, Search and Manage Memory via End-to-End Reinforcement Learning
How can we assess human-agent interactions? Case studies in software agent design
Antibody drugs show promise for treating bird flu and HIV
Nature, Published online: 05 November 2025; doi:10.1038/d41586-025-03540-4
Scientists are developing antibodies to track the evolution of these viruses and better treat infections.From Passive to Proactive: A Multi-Agent System with Dynamic Task Orchestration for Intelligent Medical Pre-Consultation
Digital Twin based Automatic Reconfiguration of Robotic Systems in Smart Environments
Diffusion Models at the Drug Discovery Frontier: A Review on Generating Small Molecules versus Therapeutic Peptides
Diagnosing Hallucination Risk in AI Surgical Decision-Support: A Sequential Framework for Sequential Validation
How Far Are Surgeons from Surgical World Models? A Pilot Study on Zero-shot Surgical Video Generation with Expert Assessment
A Survey on Cache Methods in Diffusion Models: Toward Efficient Multi-Modal Generation
Generative Artificial Intelligence in Medical Education: Enhancing Critical Thinking or Undermining Cognitive Autonomy?
Can human connection amplify digital health outcomes? Familial involvement in a mobile health app
npj Digital Medicine, Published online: 03 November 2025; doi:10.1038/s41746-025-02037-8
In “A Randomized Controlled Trial of Mobile Intervention Using Health Support Bubbles to Prevent Social Frailty”, Hayashi et al. investigated the effects of using a mobile health app with family or individually. Greater improvements in social behavior and frailty were noted in participants who used the app with family. In an era of remote healthcare and app-based health interventions, Hayashi et al.’s study reminds of the importance of human connection.Leveraging artificial intelligence to validate traditional biomarkers and drug targets in liver cancer recovery: a mini review
Front Pharmacol. 2025 Oct 17;16:1697608. doi: 10.3389/fphar.2025.1697608. eCollection 2025.
ABSTRACT
Hepatocellular carcinoma (HCC) remains a leading cause of cancer death, and recovery after therapy is shaped by heterogeneous etiologies, genomes and microenvironments. Targeted and immunotherapy combinations have broadened first-line options; yet durable benefit is uneven, and serum/imaging anchors (AFP, AFP-L3%, PIVKA-II, LI-RADS/mRECIST) incompletely resolve residual disease or functional restoration. In this review we summarise AI-enabled radiology, digital pathology and multi-omic/liquid-biopsy analytics that test and refine traditional biomarkers and drug-target readouts, and appraise translational opportunities in composite surveillance and recovery forecasting. We also discuss enduring challenges-including assay standardisation, spectrum bias, data leakage, domain shift and limited prospective external validation-that temper implementation. By integrating established anchors (AFP/AFP-L3%, PIVKA-II, ALBI, contrast-enhanced hallmarks) with AI-derived signals (radiomics/pathomics, cfDNA methylation) and pathway contexts (VEGF-VEGFR, WNT/β-catenin), emerging strategies align predictions with clinical endpoints, individualise therapy and chart hepatic function. Our synthesis provides an appraisal of AI-traditional integration in liver cancer recovery and outlines pragmatic standards-analytical robustness, transparent reporting and prospective, guideline-conformant evaluation-required for clinical adoption. We hope these insights will aid researchers and clinicians as they implement more effective, individualised monitoring and treatment pathways.
PMID:41181592 | PMC:PMC12575369 | DOI:10.3389/fphar.2025.1697608